Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17869569 | 0.85 | ALDH1A1 (0.47) | NPC1RAB9AALDH1A1SMN1; SMN2CHRM1 | |
| SCHEMBL6239021 | 0.82 | SMN1; SMN2 (0.49) | NPC1RAB9AALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL1819086 | 0.76 | MAPT (0.61) | NPC1RAB9AALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL6331933 | 0.74 | MAPT (0.62) | NPC1RAB9AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL11402027 | 0.73 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2CHRM1HTTL3MBTL1 | |
| SCHEMBL8710504 | 0.73 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2CHRM1HTTL3MBTL1 | |
| SCHEMBL11488922 | 0.73 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2CHRM1HTTL3MBTL1 | |
| SCHEMBL21138457 | 0.73 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2CHRM1HTTL3MBTL1 | |
| SCHEMBL1292196 | 0.73 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2CHRM1HTTL3MBTL1 | |
| SCHEMBL675456 | 0.73 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2CHRM1HTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005009104-A2 | BENZOIC AND PHENYL ACETIC ACID DERIVATIVES AS HNF-4 MODULATORS | LIGAND PHARMACUETICALS INCORPORATED (US) | 2005-02-03 | — | — | WO | claimed |
| EP-0191735-B1 | NOVEL OXALURIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1990-09-12 | — | — | EP | claimed |
| EP-0191735-A2 | Novel oxaluric acid derivatives and pharmaceutical compositions containing them | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1986-08-20 | — | — | EP | claimed |
| US-20050245577-A1 | Drug for kidney failure containing oxaluric acid derivative | NIPPON ZOKI PHARMACEUTICALS CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1537866-A1 | DRUG FOR KIDNEY FAILURE CONTAINING OXALURIC ACID DERIVATIVE | Nippon Zoki Pharmaceutical Co. Ltd. (JP) | 2005-06-08 | — | — | EP | disclosed |
| WO-2005009104-A2 | BENZOIC AND PHENYL ACETIC ACID DERIVATIVES AS HNF-4 MODULATORS | LIGAND PHARMACUETICALS INCORPORATED (US) | 2005-02-03 | — | — | WO | disclosed |
| EP-0191735-B1 | NOVEL OXALURIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1990-09-12 | — | — | EP | disclosed |
| US-4708954-A | DIABETES-ORAL ADMINISTRATION | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1987-11-24 | — | — | US | disclosed |
| EP-0191735-A2 | Novel oxaluric acid derivatives and pharmaceutical compositions containing them | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1986-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245577-A1 | Drug for kidney failure containing oxaluric acid derivative | OAT, OTC, OGFRL1 | NPC1 3284/4885RAB9A 3244/4885ALDH1A1 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.